Research programme: melanoma vaccine - Immune Response BioPharma

Drug Profile

Research programme: melanoma vaccine - Immune Response BioPharma

Alternative Names: IR-222; MelanoVax

Latest Information Update: 05 Feb 2014

Price : $50

At a glance

  • Originator Immune Response BioPharma
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malignant melanoma

Most Recent Events

  • 13 Dec 2013 Preclinical trials in Malignant melanoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top